114 related articles for article (PubMed ID: 18645262)
21. Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines.
Kim SH; Ho JN; Jin H; Lee SC; Lee SE; Hong SK; Lee JW; Lee ES; Byun SS
Investig Clin Urol; 2016 Jan; 57(1):63-72. PubMed ID: 26966728
[TBL] [Abstract][Full Text] [Related]
22. Integrative PDGF/PDGFR and focal adhesion pathways are downregulated in ERCC1-defective non-small cell lung cancer undergoing sodium glycididazole-sensitized cisplatin treatment.
He L; Wang X; Liu K; Wu X; Yang X; Song G; Zhang B; Zhong L
Gene; 2019 Apr; 691():70-76. PubMed ID: 30584903
[TBL] [Abstract][Full Text] [Related]
23. [Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing 1 gene in ovarian cancer cell lines].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Fu Chan Ke Za Zhi; 2006 May; 41(5):339-42. PubMed ID: 16762192
[TBL] [Abstract][Full Text] [Related]
24. Association of DNA Repair and Drug Transporter in Relation to Chemosensitivity in Primary Culture of Thai Gastric Cancer Patients.
Wongsirisin P; Limpakan Yamada S; Yodkeeree S; Punfa W; Limtrakul P
Biol Pharm Bull; 2018; 41(3):360-367. PubMed ID: 29491212
[TBL] [Abstract][Full Text] [Related]
25. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
Zhang C; Wang M; Shi C; Shi F; Pei C
Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351
[TBL] [Abstract][Full Text] [Related]
26.
Hou XF; Xu LP; Song HY; Li S; Wu C; Wang JF
World J Gastroenterol; 2017 Mar; 23(10):1796-1803. PubMed ID: 28348485
[TBL] [Abstract][Full Text] [Related]
27. Gene expression profiling of the response of esophageal carcinoma cells to cisplatin.
Takashima N; Ishiguro H; Kuwabara Y; Kimura M; Mitui A; Mori Y; Mori R; Tomoda K; Hamaguchi M; Ogawa R; Katada T; Harada K; Fujii Y
Dis Esophagus; 2008; 21(3):230-5. PubMed ID: 18430104
[TBL] [Abstract][Full Text] [Related]
28. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
29. Zinc ribbon domain-containing 1 (ZNRD1) mediates multidrug resistance of leukemia cells through regulation of P-glycoprotein and Bcl-2.
Hong L; Piao Y; Han Y; Wang J; Zhang X; Du Y; Cao S; Qiao T; Chen Z; Fan D
Mol Cancer Ther; 2005 Dec; 4(12):1936-42. PubMed ID: 16373708
[TBL] [Abstract][Full Text] [Related]
30. Krüppel-Like Factor 4 Enhances Sensitivity of Cisplatin to Esophageal Squamous Cell Carcinoma (ESCC) Cells.
Chen C; Ma Z; Zhang H; Liu X; Yu Z
Med Sci Monit; 2017 Jul; 23():3353-3359. PubMed ID: 28694421
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellular carcinoma.
Ueda S; Shirabe K; Morita K; Umeda K; Kayashima H; Uchiyama H; Soejima Y; Taketomi A; Maehara Y
Ann Surg Oncol; 2011 Apr; 18(4):1204-11. PubMed ID: 21076943
[TBL] [Abstract][Full Text] [Related]
32. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
Olaussen KA; Mountzios G; Soria JC
Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
[TBL] [Abstract][Full Text] [Related]
33. Targeting the Bcl-2 family and P-glycoprotein reverses paclitaxel resistance in human esophageal carcinoma cell line.
Shi X; Dou Y; Zhou K; Huo J; Yang T; Qin T; Liu W; Wang S; Yang D; Chang L; Wang C
Biomed Pharmacother; 2017 Jun; 90():897-905. PubMed ID: 28441715
[TBL] [Abstract][Full Text] [Related]
34. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
35. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):184-7. PubMed ID: 18756932
[TBL] [Abstract][Full Text] [Related]
36. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
Cobo M; Isla D; Massuti B; Montes A; Sanchez JM; Provencio M; Viñolas N; Paz-Ares L; Lopez-Vivanco G; Muñoz MA; Felip E; Alberola V; Camps C; Domine M; Sanchez JJ; Sanchez-Ronco M; Danenberg K; Taron M; Gandara D; Rosell R
J Clin Oncol; 2007 Jul; 25(19):2747-54. PubMed ID: 17602080
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of ZNRD1 promotes multidrug-resistant phenotype of gastric cancer cells through upregulation of P-glycoprotein.
Shi Y; Zhang Y; Zhao Y; Hong L; Liu N; Jin X; Pan Y; Fan D
Cancer Biol Ther; 2004 Apr; 3(4):377-81. PubMed ID: 14726695
[TBL] [Abstract][Full Text] [Related]
38. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2.
Ko JC; Su YJ; Lin ST; Jhan JY; Ciou SC; Cheng CM; Chiu YF; Kuo YH; Tsai MS; Lin YW
Lung Cancer; 2010 Aug; 69(2):155-64. PubMed ID: 19962780
[TBL] [Abstract][Full Text] [Related]
39. Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas.
Chen HY; Shao CJ; Chen FR; Kwan AL; Chen ZP
Int J Cancer; 2010 Apr; 126(8):1944-1954. PubMed ID: 19626585
[TBL] [Abstract][Full Text] [Related]
40. Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1).
Tsai MS; Weng SH; Kuo YH; Chiu YF; Lin YW
Mol Pharmacol; 2011 Jul; 80(1):136-46. PubMed ID: 21493726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]